Skip to search formSkip to main contentSkip to account menu

E7389

Known as: E 7389, E-7389 
A synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. E7389 binds to the… 
National Institutes of Health

Related topics

Related topics

3 relations
ER-086526eribulin mesylate

Broader (1)

eribulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1…
Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes… 
Review
2012
Review
2012
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
2012
2012
Synthesis of alcohols from m-fluorophenylsulfones and dialkylboranes: application to the C14-C35 building block of E7389.
The reaction of m-fluorophenylsulfone anions with dialkylboranes, followed by alkaline hydroperoxide oxidation, yields alcohols… 
2010
2010
Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group…
10031 Background: Eribulin is a synthetic analogue of halichondrin B derived from marine sponges. It inhibits microtubule… 
2010
2010
ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
4556 Background: Eribulin mesylate (E7389), a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits… 
Highly Cited
2009
Highly Cited
2009
New syntheses of E7389 C14-C35 and halichondrin C14-C38 building blocks: reductive cyclization and oxy-Michael cyclization approaches.
Cr-mediated coupling reactions are usually achieved with a slight excess of a given nucleophile. To develop a cost-effective use… 
Review
2008
Review
2008
Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy
1084 Background: Eribulin mesylate (E7389) is a non-taxane microtubule dynamics inhibitor with a novel mechanism of action. This… 
Review
2007
Review
2007
Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)
7546 Background: Eribulin is a structurally-simplified, fully synthetic analog of the marine sponge natural product halichondrin… 
2007
2007
Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer
1034 Background: Eribulin is a structurally simplified analog of halichondrin B, which inhibits microtubule dynamics via a novel… 
2005
2005
Phase I study of E7389 administered by 1 hour infusion every 21 days
2054 Background: E7389 is a synthetic analog of halichondrin B, which was isolated from a marine sponge and has a unique profile… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)